non-invasive in vivo imaging of tumor-associated cd133prominin肿瘤相关cd133prominin体内非侵入性成像.pdfVIP

Non-Invasive In Vivo Imaging of Tumor-Associated CD133/Prominin 1 5 1 1 2 3 Chizuko Tsurumi , Norbert Esser , Elke Firat , Simone Gaedicke , Marie Follo , Martin Behe , Ursula ¨ 4 1 5 1 Elsasser-Beile , Anca-Ligia Grosu , Ralph Graeser , Gabriele Niedermann * 1 Department of Radiation Oncology, University Hospital Freiburg, Freiburg, Germany, 2 Department of Internal Medicine I, University Hospital Freiburg, Freiburg, Germany, 3 Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany, 4 Department of Urology, University Hospital Freiburg, Freiburg, Germany, 5 ProQinase GmbH, Freiburg, Germany Abstract Background: Cancer stem cells are thought to play a pivotal role in tumor maintenance, metastasis, tumor therapy resistance and relapse. Hence, the development of methods for non-invasive in vivo detection of cancer stem cells is of great importance. Methodology/Principal Findings: Here, we describe successful in vivo detection of CD133/prominin, a cancer stem cell surface marker for a variety of tumor entities. The CD133-specific monoclonal antibody AC133.1 was used for quantitative fluorescence- based optical imaging of mouse xenograft models based on isogenic pairs of CD133 positive and negative cell lines. A first set consisted of wild-type U251 glioblastoma cells, which do not express CD133, and lentivirally transduced CD133-overexpressing U251 cells. A second set made use of HCT116 colon carcinoma cells, which uniformly express CD133 at levels comparable to primary glioblastoma stem cells, and a CD133-negative HCT116 derivative. Not surprisingly, visualization and quantification of